Overview

MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.